• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项关于已发表的样本均值和方差药代动力学数据的贝叶斯荟萃分析及其在药物相互作用预测中的应用。

A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction.

作者信息

Yu Menggang, Kim Seongho, Wang Zhiping, Hall Stephen, Li Lang

机构信息

Division of Biostatistics, Department of Medicine, School of Medicine, Indiana University, Indianapolis, Indiana 46023, USA.

出版信息

J Biopharm Stat. 2008;18(6):1063-83. doi: 10.1080/10543400802369004.

DOI:10.1080/10543400802369004
PMID:18991108
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2737821/
Abstract

In drug-drug interaction (DDI) research, a two-drug interaction is usually predicted by individual drug pharmacokinetics (PK). Although subject-specific drug concentration data from clinical PK studies on inhibitor or inducer and substrate PK are not usually published, sample mean plasma drug concentrations and their standard deviations have been routinely reported. Hence there is a great need for meta-analysis and DDI prediction using such summarized PK data. In this study, an innovative DDI prediction method based on a three-level hierarchical Bayesian meta-analysis model is developed. The three levels model sample means and variances, between-study variances, and prior distributions. Through a ketoconazle-midazolam example and simulations, we demonstrate that our meta-analysis model can not only estimate PK parameters with small bias but also recover their between-study and between-subject variances well. More importantly, the posterior distributions of PK parameters and their variance components allow us to predict DDI at both population-average and study-specific levels. We are also able to predict the DDI between-subject/study variance. These statistical predictions have never been investigated in DDI research. Our simulation studies show that our meta-analysis approach has small bias in PK parameter estimates and DDI predictions. Sensitivity analysis was conducted to investigate the influences of interaction PK parameters, such as the inhibition constant Ki, on the DDI prediction.

摘要

在药物相互作用(DDI)研究中,通常通过个体药物的药代动力学(PK)来预测两药相互作用。虽然关于抑制剂或诱导剂以及底物PK的临床PK研究中受试者特异性药物浓度数据通常不会发表,但样本平均血浆药物浓度及其标准差已被常规报告。因此,非常需要使用此类汇总的PK数据进行荟萃分析和DDI预测。在本研究中,开发了一种基于三级分层贝叶斯荟萃分析模型的创新DDI预测方法。该三级模型对样本均值和方差、研究间方差以及先验分布进行建模。通过酮康唑-咪达唑仑的实例和模拟,我们证明我们的荟萃分析模型不仅能够以较小的偏差估计PK参数,还能很好地恢复研究间和个体间的方差。更重要的是,PK参数及其方差成分的后验分布使我们能够在群体平均水平和特定研究水平上预测DDI。我们还能够预测个体间/研究间方差的DDI。这些统计预测在DDI研究中从未被探讨过。我们的模拟研究表明,我们的荟萃分析方法在PK参数估计和DDI预测方面偏差较小。进行了敏感性分析,以研究相互作用PK参数(如抑制常数Ki)对DDI预测的影响。

相似文献

1
A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction.一项关于已发表的样本均值和方差药代动力学数据的贝叶斯荟萃分析及其在药物相互作用预测中的应用。
J Biopharm Stat. 2008;18(6):1063-83. doi: 10.1080/10543400802369004.
2
Drug-drug interaction prediction: a Bayesian meta-analysis approach.药物相互作用预测:一种贝叶斯荟萃分析方法。
Stat Med. 2007 Sep 10;26(20):3700-21. doi: 10.1002/sim.2837.
3
A new probabilistic rule for drug-dug interaction prediction.一种用于药物-药物相互作用预测的新概率规则。
J Pharmacokinet Pharmacodyn. 2009 Feb;36(1):1-18. doi: 10.1007/s10928-008-9107-3. Epub 2009 Jan 21.
4
Drug-drug interaction prediction assessment.药物相互作用预测评估。
J Biopharm Stat. 2009 Jul;19(4):641-57. doi: 10.1080/10543400902964084.
5
Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.基于生理的药物相互作用代谢预测模型:酮康唑或维拉帕米合用两种细胞色素 P450 3A4 底物。
Clin Pharmacokinet. 2010 Apr;49(4):239-58. doi: 10.2165/11318130-000000000-00000.
6
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.利用生理药代动力学(PBPK)模型和最优多反应采样时间设计进行药物相互作用预测:应用于咪达唑仑和一种I期化合物。第2部分:临床试验结果。
J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):661-81. doi: 10.1007/s10928-008-9105-5. Epub 2009 Jan 7.
7
Human Pharmacokinetic and CYP3A Drug-Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment.基于生理的药代动力学模型和生物标志物评估预测 GDC-2394 的人体药代动力学和 CYP3A 药物相互作用。
Drug Metab Dispos. 2024 Jul 16;52(8):765-774. doi: 10.1124/dmd.123.001633.
8
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.酮康唑对咪达唑仑清除率的CYP3A介导抑制作用的随机预测
Drug Metab Dispos. 2006 Jul;34(7):1208-19. doi: 10.1124/dmd.105.008730. Epub 2006 Apr 12.
9
Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.基于生理的药代动力学建模,用于评估代谢性药物相互作用风险并为fedratinib的药品说明书提供依据。
Cancer Chemother Pharmacol. 2020 Oct;86(4):461-473. doi: 10.1007/s00280-020-04131-y. Epub 2020 Sep 4.
10
Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.基于半生理的药代动力学模型,用于研究地尔硫䓬及其主要代谢产物对咪达唑仑清除率的抑制作用。
Drug Metab Dispos. 2009 Aug;37(8):1587-97. doi: 10.1124/dmd.109.026658. Epub 2009 May 6.

引用本文的文献

1
Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model.采用贝叶斯基于机制的药代动力学模型评价 4β-羟基胆固醇作为 CYP3A4 药物相互作用的临床生物标志物。
CPT Pharmacometrics Syst Pharmacol. 2014 Jun 25;3(6):e120. doi: 10.1038/psp.2014.18.
2
Text mining for drug-drug interaction.药物相互作用的文本挖掘
Methods Mol Biol. 2014;1159:47-75. doi: 10.1007/978-1-4939-0709-0_4.
3
Non-compartment model to compartment model pharmacokinetics transformation meta-analysis--a multivariate nonlinear mixed model.

本文引用的文献

1
Drug-drug interaction prediction: a Bayesian meta-analysis approach.药物相互作用预测:一种贝叶斯荟萃分析方法。
Stat Med. 2007 Sep 10;26(20):3700-21. doi: 10.1002/sim.2837.
2
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.酮康唑对咪达唑仑清除率的CYP3A介导抑制作用的随机预测
Drug Metab Dispos. 2006 Jul;34(7):1208-19. doi: 10.1124/dmd.105.008730. Epub 2006 Apr 12.
3
A population pharmacokinetic model with time-dependent covariates measured with errors.一个具有测量误差的时间相依协变量的群体药代动力学模型。
非房室模型到房室模型的药代动力学转换的Meta分析——一种多元非线性混合模型
BMC Syst Biol. 2010 May 28;4 Suppl 1(Suppl 1):S8. doi: 10.1186/1752-0509-4-S1-S8.
4
Literature mining on pharmacokinetics numerical data: a feasibility study.药代动力学数值数据的文献挖掘:一项可行性研究。
J Biomed Inform. 2009 Aug;42(4):726-35. doi: 10.1016/j.jbi.2009.03.010. Epub 2009 Apr 2.
5
A new probabilistic rule for drug-dug interaction prediction.一种用于药物-药物相互作用预测的新概率规则。
J Pharmacokinet Pharmacodyn. 2009 Feb;36(1):1-18. doi: 10.1007/s10928-008-9107-3. Epub 2009 Jan 21.
Biometrics. 2004 Jun;60(2):451-60. doi: 10.1111/j.0006-341X.2004.00190.x.
4
Modeling interindividual variation in physiological factors used in PBPK models of humans.模拟人体生理药代动力学(PBPK)模型中所使用生理因素的个体间差异。
Crit Rev Toxicol. 2003;33(5):469-503.
5
Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.口服咪达唑仑与酮康唑、氟西汀、氟伏沙明和奈法唑酮的药代动力学和药效学相互作用。
J Clin Pharmacol. 2003 Nov;43(11):1274-82. doi: 10.1177/0091270003259216.
6
The effects of dose staggering on metabolic drug-drug interactions.剂量错开对代谢性药物相互作用的影响。
Eur J Pharm Sci. 2003 Oct;20(2):223-32. doi: 10.1016/s0928-0987(03)00200-8.
7
Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.半同步给予咪达唑仑在肝脏和肠道细胞色素P450 3A表型分析中的应用。
Clin Pharmacol Ther. 2002 Dec;72(6):718-28. doi: 10.1067/mcp.2002.129068.
8
Estimation and inference for a spline-enhanced population pharmacokinetic model.样条增强型群体药代动力学模型的估计与推断
Biometrics. 2002 Sep;58(3):601-11. doi: 10.1111/j.0006-341x.2002.00601.x.
9
The combination of population pharmacokinetic studies.群体药代动力学研究的结合
Biometrics. 2000 Mar;56(1):263-70. doi: 10.1111/j.0006-341x.2000.00263.x.
10
Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.将红霉素呼气试验(EBT)与口服咪达唑仑同时作为CYP3A活性的体内探针使用。
J Clin Pharmacol. 1999 Dec;39(12):1212-20. doi: 10.1177/00912709922012015.